m6A-centered Crosstalk Information

Mechanism of Crosstalk between m6A Modification and Epigenetic Regulation
Crosstalk ID
M6ACROT05010
 [1]
Non-coding RNA LINC00662 HNRNPC  lncRNA       miRNA   circRNA Direct Enhancement m6A modification AK4 AK4 hnRNPC : m6A sites
m6A Modification:
m6A Regulator Heterogeneous nuclear ribonucleoproteins C1/C2 (HNRNPC) READER
 Regulator Info 
m6A Target Adenylate kinase 4, mitochondrial (AK4)
 Targert Gene 
Epigenetic Regulation that have Cross-talk with This m6A Modification:
Epigenetic Regulation Type Non-coding RNA (ncRNA)
Epigenetic Regulator Long intergenic non-protein coding RNA 662 (LINC00662) LncRNA View Details
Regulated Target Heterogeneous nuclear ribonucleoprotein C (HNRNPC) View Details
Crosstalk Relationship ncRNA  →  m6A Enhancement
Crosstalk Mechanism ncRNAs directly impacts m6A modification through recruiting m6A regulator
Crosstalk Summary Knockdown of LINC00662 represses Adenylate kinase 4, mitochondrial (AK4) and attenuates radioresistance of oral squamous cell carcinoma.LINC00662 modulated the radiosensitivity of OSCC cells via HNRNPC-modulated AK4.
Responsed Disease Oral squamous cell carcinoma ICD-11: 2B6E.0
 Disease Info 
In-vitro Model
 CAL-27 Tongue squamous cell carcinoma Homo sapiens CVCL_1107
SCC-4 Tongue squamous cell carcinoma Homo sapiens CVCL_1684
UM-SCC-1 Floor of mouth squamous cell carcinoma Homo sapiens CVCL_7707
SCC-9 Tongue squamous cell carcinoma Homo sapiens CVCL_1685
NHOK (Normal oral keratinocytes)
Full List of Potential Compound(s) Related to This m6A-centered Crosstalk
2B6E: Head and neck squamous carcinoma 3 Compound(s) Regulating the Disease Click to Show/Hide the Full List
 Compound Name OraTest Approved [2]
External Link
TTD: D00DCY
 Compound Name Contusugene ladenovec Phase 3 [3]
Synonyms
Advexin; Ad5CMV-p53; INGN-004; INGN-201; Ad-p53, Introgen; Gene therapy (p53/adenovirus), University of Texas; Gene therapy (p53/adenoviral), Introgen/Aventis; Gene therapy (p53/adenoviral), Introgen/RPR
    Click to Show/Hide
External Link
TTD: D04FYL
 Compound Name INGN-234 Discontinued in Phase 2 [4]
Synonyms
P53 tumor suppressor (topical formulation), Introgen
    Click to Show/Hide
External Link
TTD: D05AHK
References
Ref 1 Knockdown of LINC00662 represses AK4 and attenuates radioresistance of oral squamous cell carcinoma. Cancer Cell Int. 2020 Jun 16;20:244. doi: 10.1186/s12935-020-01286-9. eCollection 2020.
Ref 2 Drugs@FDA. U.S. Food and Drug Administration. U.S. Department of Health & Human Services. 2015
Ref 3 ClinicalTrials.gov (NCT00041613) Study to Compare the Overall Survival of Patients Receiving INGN 201 (Study Drug) With Patients Receiving Methotrexate. U.S. National Institutes of Health.
Ref 4 Trusted, scientifically sound profiles of drug programs, clinical trials, safety reports, and company deals, written by scientists. Springer. 2015. Adis Insight (drug id 800028790)